Biocept Inc is an early commercial-stage molecular oncology diagnostics company. It develops and commercializes proprietary circulating tumor cell and circulating tumor DNA assays utilizing a standard blood sample.
| Website: | www.biocept.com |
| Main Phone: | +1 858 320-8200 |
| Address: | 5810 Nancy Ridge Drive |
| State: | CA |
| City / Town: | San Diego |
| Country: | USA |
| Postal Code: | 92121 |
| Exchange: | NSC |
| CEO: | Michael W. Nall |
| Employees: | 95 |
| NAICS: | Medical Laboratories(621511) |
| Last Price 2.97 | Change $ -0.08 | Change % -2.62 | Tick N/A |
| Bid 2.98 | Bid Size 200.00 | Ask 3.10 | Ask Size 200.00 |
| Open 3.05 | High 3.06 | Low 2.91 | Prev Close 3.05 |
| Last Trade | Volume 58,499 | 52 Wk Hi 40.50 | 52 Wk Low 2.86 |
| Market Cap 6.8 mi | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares 2,282,166.00 | EPS (TTM) -17.10 | PE Ratio N/A | Exchange NCM |
|
|
|
|
| Last 3 Mo | Last 12 Mo | |
|---|---|---|
| Number of Insider Trades | 0 | 2 |
| Number of Buys | 0 | 2 |
| Number of Sells | 0 | 0 |
| Net Activity | 0 | 50000 |
| Last 10 Buys | Shares |
|---|---|
| Bruce E. Gerhardt | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| David F. Hale | 1,000 |
| David F. Hale | 1,000 |
| Edward Neff | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| Bruce E. Gerhardt | 1,000 |
| Edward Neff | 1,000 |
| Veena Singh | 1,000 |
| Veena Singh | 1,000 |
| Last 10 Sell | Shares |
|---|---|
| Jeffrey H. Berg | 1,000 |
| David Pitler | 1,000 |
| David Pitler | 1,000 |
| David Pitler | 1,000 |
| Current | 1 Week Ago | 2 Weeks Ago | 3 Weeks Ago | |
|---|---|---|---|---|
| High Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Low Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Mean Target Price Estimate | 0.65 | 0.65 | 0.65 | 0.65 |
| Standard Deviation | 0 | 0 | 0 | 0 |
| Date of Most Recent Estimate | 04/03/18 | 04/03/18 | 04/03/18 | 04/03/18 |
| Form Type | Form Description | Pages | Date |
|---|---|---|---|
| 4 | Statement of changes in beneficial ownership of securities | 1 | 2018-06-06 |
| DEF 14A | Official notification to shareholders of matters to be brought to a vote (Proxy) | 108 | 2018-05-29 |
| 424B3 | Prospectus filed under Rule 424(b)(3) | 25 | 2018-05-24 |
| EFFECT | Notice from the SEC of registration effectiveness | 1 | 2018-05-24 |
| S-1 | General form for registration of securities under the Securities Act of 1933 | 60 | 2018-05-23 |
| PRE 14A | Preliminary proxy statement providing notification matters to be brought to a vote | 110 | 2018-05-17 |
| 10-Q | Quarterly report with a continuing view of a company's financial position | 66 | 2018-05-15 |
| S-3 | Simplified registration form | 160 | 2018-05-15 |
| 8-K | Report of unscheduled material events or corporate changes. | 8 | 2018-05-15 |
| 10-K/A | Amendment to a previously filed 10-K | 41 | 2018-04-30 |
| Current | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
|---|---|---|---|---|
| Strong Buy | 1 | 2 | 2 | 2 |
| Moderate Buy | 0 | 0 | 0 | 0 |
| Hold | 1 | 0 | 0 | 0 |
| Moderate Sell | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 |
| Mean Rec. | 2 | 1 | 1 | 1 |
© 2018 Equities
* All dates and time are being displayed in Eastern Standard Time (EST).
